What is Prenetics?
Founded in 2014 and now listed on Nasdaq, Prenetics is at the forefront of revolutionizing healthcare through its integrated approach encompassing Prevention, Diagnostics, and Personalized Care. Operating internationally across the United Kingdom, Hong Kong, India, South Africa, and Southeast Asia, the company offers a diverse portfolio of services. These include consumer genetic testing, early colorectal cancer screening, advanced COVID-19 testing solutions, rapid point-of-care diagnostics, at-home testing kits, and comprehensive medical genetic testing. Prenetics leverages its proprietary mobile app and sophisticated technological platforms to decentralize healthcare, ensuring diagnostic services are accessible to individuals anytime and anywhere.
How much funding has Prenetics raised?
Prenetics has raised a total of $82.7M across 4 funding rounds:
Angel/Seed
$2.6M
Series A
$10M
Series B
$40M
Other Financing Round
$30M
Angel/Seed (2014): $2.7M with participation from Coent Venture Partners, 500.com, and SXE Ventures
Series A (2016): $10M led by Lippo Group, Ping An, Venturra, COENT Venture, Capital Union Investments, and 500.com
Series B (2017): $40M supported by Venturra, Ping An Ventures, and Beyond Ventures
Other Financing Round (2024): $30M featuring Insighta
Key Investors in Prenetics
Coent Venture Partners
COENT provides seed and venture-stage funding to brilliant entrepreneurs and companies across all sectors in Asia, offering support in funding, management, and business development.
Ping An Ventures
Ping An Ventures, part of the Ping An Insurance Group, specializes in insurance, banking, and investment banking, focusing on personal financial services and strategic investments.
Venturra
Venturra is a Southeast Asia-based venture capital firm investing in early-stage, high-growth technology companies aiming to redefine industries.
What's next for Prenetics?
The substantial enterprise-level funding Prenetics has garnered signals a strong trajectory for scaling its innovative healthcare solutions. This capital infusion is expected to fuel further expansion of its diagnostic and genetic testing services, enhance its technological infrastructure, and potentially drive strategic acquisitions or partnerships. As a Nasdaq-listed entity, Prenetics is well-positioned to capitalize on market opportunities, further solidifying its commitment to making healthcare more accessible and personalized globally.
See full Prenetics company page
